Compare Illumina, Inc. (ILMN) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Prudential PLC — how do they compare? Illumina, Inc. trades at $265 (market cap $39.95B), while Prudential PLC trades at $24.03 (market cap $28.84B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Prudential PLC pays a 2.33% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Prudential PLC for 119 Days on average.
| ILMN | PUK | |
|---|---|---|
Market Cap | $39.95B | $28.84B |
Volume | 3,169,503 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $293.69 | $33.61 |
52-Week Low | $91.00 | $23.54 |
Typical Hold Time | 83 Days | 119 Days |
Enterprise Value | $41.31B | $28.38B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
PUK trades at $23.54, down 4.31% today, amid bearish technical signals. The company shows strong fundamentals with revenue growth from $16.2B in 2024 to $27.4B in 2025 and net income of $4.0B. Valuation ratios appear attractive with P/E of 8.28 and P/S of 1.01. Recent news highlights strategic shifts including emerging-market exits and a $3B capital rotation plan. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook balances solid profitability and growth against technical weakness and macroeconomic risks. Investment appeal lies in undervalued metrics and strategic refocusing, but near-term price pressure and execution risks on new initiatives warrant caution. The stock offers value for long-term investors if the company delivers on its five-year strategic targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
